Linc00665 Can Predict the Response to Cisplatin-Paclitaxel Neoadjuvant Chemotherapy for Breast Cancer Patients
ObjectiveLinc00665 is a novel long non-coding RNA that can promote the progression of breast cancer, but its value in predicting the efficacy of neoadjuvant chemotherapy (NAC) for breast cancer has not been reported. We aim to analyze the correlation between Linc00665 expression and pathological com...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-03-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.604319/full |
id |
doaj-7d7690f68d084718967e519f9a3647a4 |
---|---|
record_format |
Article |
spelling |
doaj-7d7690f68d084718967e519f9a3647a42021-03-02T08:01:17ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-03-011110.3389/fonc.2021.604319604319Linc00665 Can Predict the Response to Cisplatin-Paclitaxel Neoadjuvant Chemotherapy for Breast Cancer PatientsHuijuan DaiXiaonan ShengRui ShaJing PengFan YangLiheng ZhouYanping LinYaqian XuShan ZhangWenjin YinJinsong LuObjectiveLinc00665 is a novel long non-coding RNA that can promote the progression of breast cancer, but its value in predicting the efficacy of neoadjuvant chemotherapy (NAC) for breast cancer has not been reported. We aim to analyze the correlation between Linc00665 expression and pathological complete response (pCR) in breast cancer patients.Materials and MethodsThe present study examined the predictive role of Linc00665 expression in pCR after NAC using both univariate and multivariate logistic regression analyses. Receiver operating characteristic (ROC) curve and area under curve (AUC) were utilized to evaluate the performance of Linc00665 in predicting pCR. The Kyoto Encyclopedia of Gene and Genome (KEGG) analysis and Gene Set Enrichment Analysis (GSEA) were also conducted to determine the biological processes where Linc00665 may participate in.ResultsThe present study study totally enrolled 102 breast cancer patients. The univariate analysis showed that Linc00665 level, human epidermal growth factor receptor 2 (HER2) status and hormone receptor (HR) status were correlated with pCR. The multivariate analysis showed that Linc00665 expression was an independent predictor of pCR (OR = 0.351, 95% CI: 0.125–0.936, P = 0.040), especially in patients with HR-positive/HER2-negative subtype (OR = 0.272, 95% CI: 0.104–0.664, P = 0.005). The KEGG analysis indicated that Linc00665 may be involved in drug metabolism. The GSEA analysis revealed that Linc00665 is correlated to DNA damage repair.ConclusionLinc00665 may be a potential novel predictive biomarker for breast cancer in NAC, especially for HR-positive/HER2-negative patients.https://www.frontiersin.org/articles/10.3389/fonc.2021.604319/fullbreast cancerlong non-coding RNAneoadjuvant chemotherapypredictive biomarkerpathological complete response |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Huijuan Dai Xiaonan Sheng Rui Sha Jing Peng Fan Yang Liheng Zhou Yanping Lin Yaqian Xu Shan Zhang Wenjin Yin Jinsong Lu |
spellingShingle |
Huijuan Dai Xiaonan Sheng Rui Sha Jing Peng Fan Yang Liheng Zhou Yanping Lin Yaqian Xu Shan Zhang Wenjin Yin Jinsong Lu Linc00665 Can Predict the Response to Cisplatin-Paclitaxel Neoadjuvant Chemotherapy for Breast Cancer Patients Frontiers in Oncology breast cancer long non-coding RNA neoadjuvant chemotherapy predictive biomarker pathological complete response |
author_facet |
Huijuan Dai Xiaonan Sheng Rui Sha Jing Peng Fan Yang Liheng Zhou Yanping Lin Yaqian Xu Shan Zhang Wenjin Yin Jinsong Lu |
author_sort |
Huijuan Dai |
title |
Linc00665 Can Predict the Response to Cisplatin-Paclitaxel Neoadjuvant Chemotherapy for Breast Cancer Patients |
title_short |
Linc00665 Can Predict the Response to Cisplatin-Paclitaxel Neoadjuvant Chemotherapy for Breast Cancer Patients |
title_full |
Linc00665 Can Predict the Response to Cisplatin-Paclitaxel Neoadjuvant Chemotherapy for Breast Cancer Patients |
title_fullStr |
Linc00665 Can Predict the Response to Cisplatin-Paclitaxel Neoadjuvant Chemotherapy for Breast Cancer Patients |
title_full_unstemmed |
Linc00665 Can Predict the Response to Cisplatin-Paclitaxel Neoadjuvant Chemotherapy for Breast Cancer Patients |
title_sort |
linc00665 can predict the response to cisplatin-paclitaxel neoadjuvant chemotherapy for breast cancer patients |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Oncology |
issn |
2234-943X |
publishDate |
2021-03-01 |
description |
ObjectiveLinc00665 is a novel long non-coding RNA that can promote the progression of breast cancer, but its value in predicting the efficacy of neoadjuvant chemotherapy (NAC) for breast cancer has not been reported. We aim to analyze the correlation between Linc00665 expression and pathological complete response (pCR) in breast cancer patients.Materials and MethodsThe present study examined the predictive role of Linc00665 expression in pCR after NAC using both univariate and multivariate logistic regression analyses. Receiver operating characteristic (ROC) curve and area under curve (AUC) were utilized to evaluate the performance of Linc00665 in predicting pCR. The Kyoto Encyclopedia of Gene and Genome (KEGG) analysis and Gene Set Enrichment Analysis (GSEA) were also conducted to determine the biological processes where Linc00665 may participate in.ResultsThe present study study totally enrolled 102 breast cancer patients. The univariate analysis showed that Linc00665 level, human epidermal growth factor receptor 2 (HER2) status and hormone receptor (HR) status were correlated with pCR. The multivariate analysis showed that Linc00665 expression was an independent predictor of pCR (OR = 0.351, 95% CI: 0.125–0.936, P = 0.040), especially in patients with HR-positive/HER2-negative subtype (OR = 0.272, 95% CI: 0.104–0.664, P = 0.005). The KEGG analysis indicated that Linc00665 may be involved in drug metabolism. The GSEA analysis revealed that Linc00665 is correlated to DNA damage repair.ConclusionLinc00665 may be a potential novel predictive biomarker for breast cancer in NAC, especially for HR-positive/HER2-negative patients. |
topic |
breast cancer long non-coding RNA neoadjuvant chemotherapy predictive biomarker pathological complete response |
url |
https://www.frontiersin.org/articles/10.3389/fonc.2021.604319/full |
work_keys_str_mv |
AT huijuandai linc00665canpredicttheresponsetocisplatinpaclitaxelneoadjuvantchemotherapyforbreastcancerpatients AT xiaonansheng linc00665canpredicttheresponsetocisplatinpaclitaxelneoadjuvantchemotherapyforbreastcancerpatients AT ruisha linc00665canpredicttheresponsetocisplatinpaclitaxelneoadjuvantchemotherapyforbreastcancerpatients AT jingpeng linc00665canpredicttheresponsetocisplatinpaclitaxelneoadjuvantchemotherapyforbreastcancerpatients AT fanyang linc00665canpredicttheresponsetocisplatinpaclitaxelneoadjuvantchemotherapyforbreastcancerpatients AT lihengzhou linc00665canpredicttheresponsetocisplatinpaclitaxelneoadjuvantchemotherapyforbreastcancerpatients AT yanpinglin linc00665canpredicttheresponsetocisplatinpaclitaxelneoadjuvantchemotherapyforbreastcancerpatients AT yaqianxu linc00665canpredicttheresponsetocisplatinpaclitaxelneoadjuvantchemotherapyforbreastcancerpatients AT shanzhang linc00665canpredicttheresponsetocisplatinpaclitaxelneoadjuvantchemotherapyforbreastcancerpatients AT wenjinyin linc00665canpredicttheresponsetocisplatinpaclitaxelneoadjuvantchemotherapyforbreastcancerpatients AT jinsonglu linc00665canpredicttheresponsetocisplatinpaclitaxelneoadjuvantchemotherapyforbreastcancerpatients |
_version_ |
1724240847905488896 |